At early stage of tumorigenesis, the usage of Fms-related tyrosine kinase 3 ligand (Flt3L), which could promote cDCs hematopoietic mobilization, reduced pro-tumor TH17 cells and promoted anti-tumor CD8+ CTL numbers. Here, FLT3LG is linked to neoplasm.